ST. LOUIS, Jan. 29 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) today announced that it has signed a distribution agreement with CPC Scientific, a leading provider of high quality custom peptide synthesis, GMP peptides and peptide APIs for the pharmaceutical and biotechnology industry. Under the terms of the agreement, CPC Scientific will offer Sigma-Aldrich's PEPscreen(R) custom peptide libraries (http://www.sigma.com/pepscreen) to life science researchers and pharmaceutical companies in North America. Sigma- Aldrich has developed a proprietary synthesis platform that enables the high throughput production of milligram quantities of peptides, which are ideal for producing custom peptide libraries applicable to peptide based drug discovery.
"In Sigma-Aldrich, we've found an experienced partner for the production of custom peptide libraries," said Dr. Shawn Lee, President & CEO of CPC Scientific. "The addition of PEPscreen custom peptide libraries to our portfolio benefits our customers by addressing the early research phase of peptide screening in the drug discovery workflow."
Sigma-Aldrich's peptide synthesis process significantly reduces the time required for peptide library development, reducing costs in the drug development process. The company's customized peptide libraries are utilized by the biotechnology industry to target active areas of small biological molecules with potential therapeutic properties.
"Our PEPscreen technology enables small scale, early stage drug candidate screenings," said Stacey Hoge, Senior Product Manager at Sigma-Aldrich. "CPC's close association with the pharmaceutical and biotechnology industry provides great opportunities for Sigma-Aldrich to further engage drug discovery researchers."
For more information on Sigma-Aldrich's comprehensive PEPscreen custom peptide library offering, please visit http://www.sigma.com/pepscreen.
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 37 countries and has 8,000 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.
About CPC Scientific Inc.: CPC Scientific is an eight-year-old company headed by Dr. Shawn Lee who was formerly the owner and COO of the American Peptide Company for 15 years. CPC Scientific has a state-of-the-art, ISO Certified and cGMP licensed 30,000 sq. foot production facility with 150 full- time employees. The Company produces approximately 1,000 custom peptides per month ranging in quantity from milligrams to multiple kilograms with purities from crude peptide to 99% purity with an average three-week delivery. CPC Scientific can also produce almost all commercially available peptide modifications. All peptides are delivered with full documentation including HPLC, Mass Spectrometry and solubility information plus a 100% Customer Satisfaction Guarantee. The Company has in-house AAA capabilities. For more information about CPC Scientific, please visit the Web site at http://www.cpcscientific.com
Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Companies' expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Companies' operations and conditions in the markets the Companies serve. The Companies do not undertake any obligation to update these forward-looking statements.
Copyright©2009 PR Newswire.
All rights reserved